Saturated Fat Intake and Replacement

Nucleus of the dietary-fat cluster. WHO’s 2023 guideline, and the first domain finding in this wiki. Its structure matters as much as its numbers: the recommendation splits by replacement nutrient, and the strength differs across the splits.

The recommendations, with their strength and certainty

#	Recommendation	Strength	Overall certainty
1	Reduce SFA intake to 10% of total energy	strong	moderate
2	Further reduce to less than 10% of total energy	conditional	very low
3a	Replace SFA with polyunsaturated fatty acids	strong	moderate *
3b	Replace SFA with monounsaturated fatty acids from plant sources	conditional	low *
3c	Replace SFA with carbohydrates from foods containing naturally occurring dietary fibre (whole grains, vegetables, fruits, pulses)	conditional	low

[EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Executive summary; Recommendations]

* There is no inconsistency here, though it looks like one. WHO does not assign contradictory certainty to the same comparison. The “low PUFA / moderate plant-MUFA” figures are scoped to “prospective observational studies in the systematic review by Reynolds et al.”; the “moderate PUFA” figure comes from “RCTs and strictly controlled feeding trials” and Hooper’s RCT subgroup. Both sentences say “overall” at different scopes — within the observational body, versus across study types — which is confusing wording, not a contradiction. Per-design rating is exactly what GRADE prescribes. A correct practice was scored as a defect, and the claim was propagated to three pages plus the hub before a blind audit caught it. The real finding A follow-up attempt to find a real discrepancy in this neighbourhood (a roll-up “departure”) was also falsified, before commit. See Rating Certainty of Evidence for what GRADE 5.4 actually says.

Superseded text, kept for the record: the rationale for recommendation 3 (and the executive summary) assigns moderate to PUFA and low to MUFA. But the Summary of evidence, the Evidence to recommendations section, and the Annex 7 evidence-to-decision table all assign moderate to plant-based MUFA and low to PUFA — and the Annex 6 evidence profile for the PUFA replacement shows every hard outcome at Low or Very low. Similarly rec 2 is “very low” in its rationale and “low” in three other places. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Rationale for SFA recommendation 3; Summary of evidence; Evidence to recommendations; Annex 6; Annex 7]

This is a finding, not a transcription problem. WHO’s strength rationale for the strong PUFA recommendation cites “moderate certainty overall” — so the strongest replacement recommendation in the guideline rests on the contested cell. Run Was GRADE Actually Used criterion 3 (per-outcome rating, consistently reported) against it.

Trans-fatty acids follow the same shape at a different threshold: reduce to 1% of energy (strong), further reduce below 1% (conditional), replace with PUFA or MUFA “primarily from plant sources” (conditional).

What the evidence actually showed

• RCTs: reducing SFA reduced CVD risk in adults (moderate certainty), and greater reductions produced greater risk reduction — a dose-response gradient. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Rationale for SFA recommendations 1 and 2]
• All-cause mortality is weaker than WHO’s own summary sentence implies. The summary says lower SFA “reduced the risk of all-cause mortality and CVDs”, but the pooled estimates for all-cause mortality are non-significant (RCT RR 0.96, 95% CI 0.90-1.03; observational RR 0.93, 0.86-1.00), and WHO states elsewhere that reducing SFA “did not appear to have an effect on risk of all-cause mortality.” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Summary of evidence] The CVD finding is the one that carries the recommendation.
• The 10% threshold is where the evidence stops, not where the biology does. Stepwise testing of intake thresholds “did not find a clear effect on any cardiovascular or mortality outcome at SFA intakes of less than 10% of total energy intake” — but significant reductions in CVD and CVD mortality were observed below 9%. WHO’s own summary: “there is ample evidence supporting reduction of SFA intake to 10% of total energy, but only limited evidence supporting a reduction to below 10%.” Almost all trials had baseline SFA above 10%, so the sub-10% range is thinly studied rather than shown to be flat.
• Observational: lower SFA associated with reduced all-cause mortality (very low certainty); below-10% versus above-10% (low certainty).
• On LDL, all three replacements work, with high certainty. Replacing SFA with PUFA, MUFA or carbohydrates all reduced LDL cholesterol (high certainty), the effect is cumulative — “the more SFA intake is reduced, the more LDL cholesterol is lowered” — and it was observed down to SFA intakes of 2% of total energy. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Rationale for SFA recommendations 1 and 2]
  • That LDL reduction is causally meaningful, not just a moved marker -> LDL ApoB and Cumulative Exposure (LDL/apoB causes ASCVD; risk falls in proportion to the reduction achieved x its duration). This reframes the small events effect below: a modest LDL drop sustained over decades is worth more than the short-trial RR suggests — but the caveat cuts too, since the SFA->LDL effect is itself modest, and in the metabolically-impaired LDL-C can understate the apoB particle change.

The replacements are NOT equivalent on LDL. High certainty attaches to all three, but the magnitudes are explicitly rank-ordered: “the greatest reduction in LDL cholesterol was observed for polyunsaturated fatty acids, followed by monounsaturated fatty acids and then carbohydrates” — -0.055 / -0.042 / -0.033 mmol/L per 1% of energy exchanged. PUFA and MUFA additionally lowered triglycerides and both cholesterol ratios. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Rationale for SFA recommendation 3; Summary of evidence]

So PUFA’s stronger recommendation is over-determined: it has both the largest lipid effect and (on the rec-3 rationale) the better hard-outcome evidence. What the structure does show is that certainty on the surrogate is uniformly higher than certainty on the outcomes it stands for — high for LDL, moderate-to-low for the clinical endpoints. That asymmetry, not an equivalence among replacements, is the transferable point. [INFERRED (WHO - Saturated and Trans Fatty Acid Intake 2023) — entailment from the two certainty sets.]

CORRECTION (2026-07-25, blind cold-audit). This section first claimed the replacements were near-equivalent on the surrogate and that PUFA’s advantage rested on hard-outcome evidence alone. WHO’s explicit LDL ranking falsifies that. Recorded rather than silently amended: the original claim was an inference drawn from certainty labels without checking the magnitudes underneath them.

The absolute effects (Annex 6 second pass, 2026-07-26)

The recommendations above are stated as strength + certainty. Those cannot be ranked against anything. These can. All figures are WHO’s own, per 1000 people, at the event rate observed in the studies. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Annex 6, evidence profiles 1, 5, 7 and 9]

Lower vs higher SFA intake, adults (profile 1, RCTs):

Outcome	RR (95% CI)	Absolute per 1000	Certainty
All-cause mortality	0.96 (0.90-1.03)	2 fewer (6 fewer to 2 more)	Moderate
CVD mortality	0.94 (0.78-1.13)	1 fewer (4 fewer to 2 more)	Low
Cardiovascular diseases	0.83 (0.70-0.98)	15 fewer (25 fewer to 2 fewer)	Moderate
CHD mortality	0.97 (0.82-1.16)	1 fewer (3 fewer to 3 more)	Low
CHD (fatal + non-fatal)	0.83 (0.68-1.01)	7 fewer (14 fewer to 0)	Very low
Stroke	0.92 (0.68-1.25)	2 fewer (7 fewer to 6 more)	Very low

The headline number is 15 fewer cardiovascular events per 1000 — about 1.5 percentage points, on a control event rate of 8.5%. It is the only hard outcome in the profile that excludes the null. No mortality outcome does: all-cause 2 fewer, CVD mortality 1 fewer, CHD mortality 1 fewer, every interval spanning no effect. A reader who takes “strong recommendation” to mean this saves lives, measurably is reading something the profile does not contain. [INFERRED (WHO - Saturated and Trans Fatty Acid Intake 2023) — entailment from the profile; WHO does not summarize it this way.]

By replacement (RCTs, cardiovascular diseases):

Replacement	RR (95% CI)	Absolute per 1000	Control event rate	Certainty
PUFA	0.79 (0.62-1.00)	50 fewer (91 fewer to 0)	23.8%	Low
Carbohydrate	0.84 (0.67-1.06)	12 fewer (25 fewer to 5 more)	7.6%	Low
Plant MUFA	3.00 (0.33-26.99)	77 more (26 fewer to 1000 more)	0.4% [sic — 1/26 = 3.8%]	Very low

Do not read the 50-vs-12 gap as PUFA outperforming carbohydrate by 4x. The PUFA trials ran in a population with a 23.8% control event rate against 7.6% — roughly three times the baseline risk. That is Baseline Risk and the Relative-Absolute Split operating in the wild: most of the absolute gap is the population, not the nutrient. The relative effects (0.79 vs 0.84) are far closer than the absolute ones, and both intervals touch or cross 1.00. [INFERRED (WHO - Saturated and Trans Fatty Acid Intake 2023) — entailment from the event rates recorded in the profiles.]

The MUFA row is a warning about reading certainty labels as evidence weight. The plant-MUFA RCT evidence is a single trial, 52 participants, 4 events, giving RR 3.00 with an interval running to 26.99 — rated Very low, correctly. WHO says so in prose: “only one small trial with olive oil as an intervention was included in the monounsaturated fatty acids subgroup.” WHO’s moderate certainty for plant MUFA comes entirely from observational data — for cardiovascular diseases, RR 0.90 (0.84-0.96), 7 fewer per 1000, 3 studies, Moderate, upgraded for dose-response. So the MUFA recommendation is observational-only in substance, and the RCT evidence that exists points the other way on numbers too small to mean anything.

Two traps in this row, both of which this page previously fell into. The Annex 6 study-count cell reads 16 — that is the count 1 run together with footnote marker 6, whose text is “Only one study included.” And the frequently-quoted RR 0.85 (0.82-0.88) / 36 fewer per 1000 for plant MUFA is the all-cause mortality row, not the cardiovascular one; importing it into a CVD table overstates the absolute benefit five-fold.

Replacement is conditional on energy balance

The guidance on replacement nutrients “is relevant for a state of energy balance, in which total energy consumed is balanced by total energy expended… In cases of positive energy balance, and where a reduction in total energy intake is desired, SFA intake may be reduced in part or entirely without the need for a replacement nutrient.” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Remarks for Recommendation 3]

So the comparator is not fixed: in energy balance the question is SFA versus what, and in energy surplus it can be SFA versus nothing. A recommendation to replace SFA with PUFA is silently conditioned on an energy assumption that often will not hold for the person reading it — which makes this a worked case of why a comparator must be stated (Framing a Decision Question).

The food matrix — named, acknowledged, and not resolved

WHO records that “different SFA-containing foods, such as dairy foods, may have differential effects on risk of CVDs and type 2 diabetes, as a result of either differing compositions of SFAs across foods, other constituents of the foods (i.e. the ‘food matrix’) or a combination of the two” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Background] — and then files it as a research gap, calling for work to “compare the health effects of SFA from different food sources (e.g. plant, animal, dairy, specific oils), taking into consideration the nature of the replacement nutrient(s) or food(s).” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Research gaps]

The recommendations are therefore nutrient-level, not food-level — and the stated reason is a scope decision, not an evidence judgment: “considering the effects of specific foods or classes of foods is beyond the scope of this guideline.” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Scope] WHO’s separate insufficiency finding covers individual SFA (which specific fatty acids), a different question.

So the guidance does not distinguish butter from cheese from yoghurt at matched SFA, and the reason is that it never asked — with the question then filed as a research gap. That is materially different from either an oversight or a considered verdict of no-difference, and it leaves the question open rather than closed.

Decision relevance

• The threshold and the replacement are two separate decisions, and the second is where the evidence is thinnest. Eat less saturated fat without a replacement names half a recommendation.
• Below 10% is weakly supported, and WHO says so — the conditional recommendation rests on very low certainty, adopted as “a conservative approach” because no countervailing harm was found, not because benefit was confidently demonstrated — WHO records evidence “suggested reduced risk of CVDs with SFA intakes of less than 10%”, at very low certainty.
• If you are in energy surplus and reducing intake, the replacement question may not arise at all.
• Do not read the LDL evidence as the outcome evidence. High certainty attaches to the lipid change; moderate-to-low certainty attaches to what follows from it.

Willett (2012) — a DISTINCTION, not a tension (filed then retracted, 2026-07-25)

A tension page was minted claiming WHO and Willett clash on whether LDL licenses the SFA-to-carbohydrate recommendation. A blind audit found the framing false and it was retracted the same day. What survives is a distinction plus two durable decision rules.

They report the same answer — and it is NOT independent confirmation (corrected 2026-07-26). The figures below were previously presented here as WHO and Willett independently converging, under the heading where they AGREE, which is the decisive fact. That framing was wrong and is retracted. Willett attributes his numbers to “a pooled analysis of original data (Jakobsen et al., 2009)” [EXTRACTED (Willett - Nutritional Epidemiology 3e) Ch 19].

But the correction over-shot, and the denial of independence does not hold either. WHO’s replacement estimates do not come from Jakobsen. Its RCT figure is “Subgroup analysis of RCTs in the systematic review by Hooper et al.” — 4 trials, 51 104 participants — and its observational replacement evidence is attributed to Reynolds et al. Jakobsen 2009 appears in WHO’s reference list (ref 10) cited in the Background narrative; presence in a reference list is not provenance for an estimate. So the two numbers placed side by side here are a cohort pooled analysis (Willett/Jakobsen) and an RCT pooled analysis (WHO/Hooper) — different designs, different trial sets.

Which leaves the pairing genuinely unresolved rather than settled either way. It is not the laundered-E it was first written as, and not the shared-primary-study it was then corrected to. What can be said: the estimates are not commensurable enough to bank as independent corroboration, because nothing here establishes that the cohort and RCT bodies are non-overlapping in their underlying populations. The decision rules below rest on the evidence itself, not on a witness count.

What each source reports: on disease outcomes for the carbohydrate arm both find essentially nothing. WHO’s RCT subgroup analysis “showed a reduction in risk of CVDs and coronary heart disease when SFA were replaced with polyunsaturated fatty acids (moderate certainty evidence), but not when SFA were replaced by carbohydrates”; its Annex 6 profile for that arm gives CHD RR 0.93 (0.78-1.11). [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Summary of evidence; Annex 6] Willett’s pooled cohorts give SFA vs carbohydrate RR 0.97 (0.81-1.16), against SFA vs PUFA RR 1.25 (1.01-1.56). [EXTRACTED (Willett - Nutritional Epidemiology 3e) Ch 19 (p.436)] Both rank PUFA first. WHO’s carbohydrate recommendation is conditional on low certainty for exactly this reason.

The real difference is a classification one, and WHO states its reason. WHO grades LDL a critical outcome and the ratios/triglycerides important, “noting that the evidence supporting their use… was less certain.” Willett argues the total/HDL ratio is the better predictor and that total cholesterol — not LDL — should not carry the diet-CHD inference; he explicitly holds that prediction “using serum total cholesterol is less powerful than by using… the LDL and HDL lipid fractions.” [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Summary of evidence; (Willett - Nutritional Epidemiology 3e) Ch 19 (pp.431-432)]

And WHO engages Willett’s mechanism rather than missing it: it records the Mensink finding of “a slight increase in triglycerides and a reduction in high-density lipoprotein (HDL) cholesterol when SFA are replaced by carbohydrates of mixed composition. However, the clinical relevance of such changes is not clear”, citing a 2019 rebuttal that postdates Willett’s edition. [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Summary of evidence]

Two durable rules survive, and they were the real product:

• Never accept replace saturated fat without the replacement named. The same pooled data give a null against carbohydrate and RR 1.25 against PUFA — the substitution sets the sign.
• Carbohydrate quality is load-bearing, and both parties say so. WHO specifies “whole grains and foods… having a low glycaemic index”; Willett reports the SFA association is “positive if compared with lower GI carbohydrates but null if compared with average or higher GI carbohydrates.” [EXTRACTED (Willett - Nutritional Epidemiology 3e) Ch 19 (p.453)]

Limits

• Recommendations are nutrient-level; food-level and dietary-pattern-level effects are explicitly unresolved (above).
• The sub-10% range is under-studied rather than shown flat — an absence of evidence at those intakes, with the sub-9% signal cutting the other way.
• This page carries the guideline’s conclusions and certainty structure. The full GRADE evidence profiles (Annex 6), the evidence-to-decision tables (Annex 7), and the effect magnitudes per outcome are extracted above (Annex 6 second pass). The evidence-to-decision tables (Annex 7) remain unextracted.
• The control event rates WHO prints are not all internally consistent — the plant-MUFA RCT row gives “1/26 (0.4%)” where 1/26 = 3.8%, and WHO’s own absolute effect (77 more per 1000 at RR 3.00) implies 3.8%. Reproduced above as printed, flagged rather than silently corrected.
• No longer single-source: Willett is ingested and cited throughout. What is still absent is an independent appraisal of the same evidence base by a second guidance body — Hooper 2020 (added 2026-07-29) is not that: it is the upstream Cochrane MA whose RCT estimates WHO adopted, so it strengthens warrant on the numbers without adding an independent witness (see the Hooper section).

Why SFA intake cannot be rescued by a biomarker [2026-07-28, Willett ch.8]

Everything on this page rests on self-reported saturated-fat intake. The obvious remedy — measure it in blood or tissue instead — is closed off, and Van Dam & Hunter say why:

«However, biomarkers of fatty acids can also have serious limitations. Biomarkers generally perform poorly for fatty acids that can be produced endogenously, including even-chained saturated and monounsaturated fatty acids. Furthermore, although biomarkers appear “objective,” the use of fatty acid biomarkers can introduce bias and confounding that is not present for studies of fatty acid intakes.» [EXTRACTED (Willett - Nutritional Epidemiology 3e) chunk 10]

The mechanism is endogenous synthesis. A tissue concentration of a fatty acid the body makes is a function of intake and of de novo lipogenesis, which is itself driven by carbohydrate intake, energy balance and insulin status. The biomarker measures the sum and cannot separate the terms.

Three consequences for how this page’s evidence should be read.

• Self-report is not a remediable weakness here; it is the ceiling. For SFA and MUFA there is no better instrument waiting to be applied. That is different from a literature that could be upgraded and has not been.
• The reliability of “fat” evidence varies sharply by fat type, and the split is mechanistic: fatty acids the body cannot synthesise (trans fats, long-chain n-3) have informative biomarkers; those it can (even-chain saturated, monounsaturated) do not. This is a within-category boundary that carries real information -> Is the Food Category Doing Any Work. It is also a partial explanation for why the trans-fat signal is the firmest fat finding the corpus holds.
• The third sentence is the one to keep. Willett’s chapter states that fatty-acid biomarkers can introduce bias and confounding «not present for studies of fatty acid intakes» — so substituting a biomarker is not a strictly-safer choice. The apparent objectivity of a biochemical measure is not the same as freedom from confounding, and here it can run the other way. [INFERRED (Willett - Nutritional Epidemiology 3e) — the de-novo-lipogenesis mechanism and the by-fat-type reliability split are this page's; the limitation and the bias warning are Van Dam & Hunter's]

What this does NOT do. It does not weaken any specific estimate on this page. WHO’s trials measured assigned diets, not biomarkers, and the cohort evidence’s measurement problem was already recorded. This says the problem is structural rather than fixable -> Measurement Error in Dietary Assessment.

A third guidance family — same number, same replacement hierarchy [2026-07-28, ESC]

ESC - CVD Prevention Guidelines 2021 Table 8:

«Saturated fatty acids should account for <10% of total energy intake, through replacement by PUFAs, MUFAs, and carbohydrates from whole grains» [EXTRACTED (ESC - CVD Prevention Guidelines 2021) chunk 04, Table 8]

Parameter table against the WHO recommendations already on this page:

Parameter	WHO 2023	ESC 2021	Same quantity?
Threshold	<10% of total energy	<10% of total energy	YES
Replacements named	PUFA; MUFA from plant sources; carbohydrate from foods containing naturally occurring dietary fibre	PUFA; MUFA; carbohydrate from whole grains	near — ESC omits WHO’s plant sources qualifier on MUFA
Ordering of replacements	PUFA strong, MUFA and carbohydrate conditional	listed in the same order, no strength attached	NO — ESC grades nothing here
Certainty on the threshold	moderate	not stated in Table 8	NO

The threshold matches exactly and the replacement list matches nearly. What ESC does not carry is the structure: WHO separates a strong PUFA recommendation from conditional MUFA and carbohydrate ones, at different certainties. ESC’s table presents all three as one undifferentiated instruction.

So a reader taking ESC alone would not learn what this page’s central finding is — that the three replacements are not equivalent, and that PUFA’s stronger recommendation is over-determined by having both the largest lipid effect and the firmer evidence. The information loss is in the presentation, not the position: ESC’s ordering happens to match WHO’s strength ordering, but nothing in the table says so. [INFERRED (ESC - CVD Prevention Guidelines 2021; WHO - Saturated and Trans Fatty Acid Intake 2023) — each cell is quoted; the observation about lost structure is this page's]

NOT filed as independent corroboration. Two guidance bodies reaching the same threshold is the configuration this corpus has repeatedly found to be non-independent, and the wiki has not checked ESC’s evidence base for this line — Table 8 carries no references. Absence of a check is not evidence of independence, so no [E-independent], and the agreement is recorded as a fact about the guidance set rather than as added confidence.

Annex 6 — the full evidence profile, with absolute effects [2026-07-28]

The source page called this «the single highest-value unextracted block in the wiki». Read from the recovered-tables sidecar (pp 79-80), which preserves the grid the flattened chunk text loses.

Reducing saturated fat intake — every graded outcome:

Outcome	Design	Studies	Relative (95% CI)	Absolute per 1000 (95% CI)	Certainty
All-cause mortality	RCT	12	RR 0.96 (0.90 to 1.03)	2 fewer (6 fewer to 2 more)	Moderate
All-cause mortality	Obs	21	RR 0.93 (0.86 to 1.00)	12 fewer (25 fewer to 0)	Very low
CVD mortality	RCT	11	RR 0.94 (0.78 to 1.13)	1 fewer (4 fewer to 2 more)	Low
Cardiovascular diseases (events)	RCT	13	RR 0.83 (0.70 to 0.98)	15 fewer (25 fewer to 2 fewer)	Moderate
Cardiovascular diseases	Obs	16	RR 0.93 (0.86 to 1.02)	4 fewer (9 fewer to 1 more)	Very low
CHD mortality	RCT	9	RR 0.97 (0.82 to 1.16)	1 fewer (3 fewer to 3 more)	Low
CHD (fatal and non-fatal)	RCT	—	RR 0.83 (0.68 to 1.01)	7 fewer (14 fewer to 0)	Very low
CHD (fatal and non-fatal)	Obs	—	RR 0.96 (0.90 to 1.03)	1 fewer (3 fewer to 1 more)	Very low
Stroke	RCT	—	RR 0.92 (0.68 to 1.25)	2 fewer (7 fewer to 6 more)	Very low
Stroke	Obs	—	RR 1.02 (0.90 to 1.16)	0 more (2 fewer to 3 more)	Low
Type 2 diabetes	—	—	RR 0.98 (0.91 to 1.06)	1 fewer (4 fewer to 3 more)	Low
LDL cholesterol (mmol/L per 1% energy exchange)	—	—	—	-0.055 (-0.061 to -0.050)	High

[EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Annex 6, pp.79-80]

Column mapping verified by arithmetic, not by eye. The flattened table interleaves outcome labels with values, so each absolute was checked against event rate x (1 - RR): CVD events 8.5% x 0.17 = 14.5 -> «15 fewer»; all-cause 6.2% x 0.04 = 2.5 -> «2 fewer»; CVD mortality 1.9% x 0.06 = 1.1 -> «1 fewer»; CHD 4.2% x 0.17 = 7.1 -> «7 fewer». Four independent confirmations of the column alignment.

Four findings, and the first one changes how this page should be read

1. Exactly ONE outcome clears the null, and it is not mortality. Cardiovascular events — 15 fewer per 1000, RR 0.83 (0.70 to 0.98), Moderate certainty, 13 RCTs. Every other interval crosses no-effect: all-cause mortality, CVD mortality, CHD mortality, CHD events, stroke, type 2 diabetes. The page’s headline was already the strongest cell in the annex; what was missing is that it is the ONLY one.

2. Reducing saturated fat does not measurably reduce dying. All-cause mortality in RCTs is 2 fewer per 1000, RR 0.96 (0.90 to 1.03) at Moderate certainty — not a thin-evidence null but a reasonably-graded one. This is a decision-relevant fact that the 10%E recommendation does not carry, and anyone reading SFA reduction as a longevity intervention is reading past the evidence.

3. The certainty gradient runs exactly opposite to the outcome importance. LDL cholesterol is the only High-certainty row in the annex; every patient-important outcome is Moderate or below, and four are Very low. The best-known quantity is the surrogate -> Surrogate Outcomes. Same structure as Sodium Intake and Blood Pressure — high certainty on the marker, very low on the outcomes it stands for. Two exposures, two guidelines, one shape.

4. RCTs and cohorts disagree on all-cause mortality, and the cohorts look better. Observational: 12 fewer per 1000, RR 0.93 (0.86 to 1.00). Randomised: 2 fewer, RR 0.96. The observational estimate is six times larger in absolute terms — and WHO grades it Very low against the RCTs’ Moderate. This is the design-class divergence Willett documents, appearing inside a single guideline’s own annex -> Measurement Error in Dietary Assessment, Upgrading Observational Evidence. Note WHO resolved it the right way — it graded the larger, more flattering estimate lower.

What this does NOT establish. These are effects of reducing SFA pooled across replacement nutrients; the replacement-specific profiles (5 and 9) are the ones already on this page, and they are a different cut of the evidence. Do not add a row from this table to a row from those.

Hooper 2020 — the Cochrane RCT meta-analysis underneath WHO’s numbers [2026-07-29]

Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020 is the primary Cochrane review (15 RCTs, 16 comparisons, 56 675 participants, all interventions >=24 months) that WHO’s RCT evidence profile rests on — WHO names it directly («Subgroup analysis of RCTs in the systematic review by Hooper et al.»). So this is not an independent second witness: the WHO Annex 6 RCT column above and Hooper’s Summary of Findings are the same trials, re-graded. Hooper adds four things WHO’s guideline does not carry: the headline in the primary source’s own voice, an NNT/time-horizon framing, the dose-response mechanism, and the effect-modification nulls.

Non-independence, cell by cell. Every RCT estimate in this page’s Annex 6 table is Hooper’s:

Outcome (RCT)	WHO Annex 6 — RR / absolute / certainty	Hooper 2020 SoF — RR / absolute / certainty	Same quantity?
All-cause mortality	0.96 (0.90-1.03) / 2 fewer / Moderate (12)	0.96 (0.90-1.03) / 62->60 per 1000 / Moderate (12)	YES — identical
CVD mortality	0.94 (0.78-1.13) / 1 fewer / Low (11)	0.94 (0.78-1.13) / 19->18 per 1000 / Moderate (11)	same estimate, certainty differs
Cardiovascular events	0.83 (0.70-0.98) / 15 fewer / Moderate (13)	0.83 (0.70-0.98) / 85->70 per 1000 / Moderate (13)	YES — identical
CHD mortality	0.97 (0.82-1.16) / 1 fewer / Low (9)	0.97 (0.82-1.16) / 16->16 per 1000 / Low (9)	YES — identical
CHD events	0.83 (0.68-1.01) / 7 fewer / Very low (11)	0.83 (0.68-1.01) / 42->35 per 1000 / Very low (11)	YES — identical
Stroke	0.92 (0.68-1.25) / 2 fewer / Very low (7)	0.92 (0.68-1.25) / 22->20 per 1000 / Very low (7)	YES — identical

[EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01, Summary of findings 1] [EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Annex 6]

The only difference across shared outcomes is CV-mortality certainty — Hooper grades it Moderate, WHO grades the identical estimate Low (WHO applied one further downgrade); neither the RR (0.94) nor the absolute (1 fewer per 1000) moves. So this page’s RCT numbers are confirmed as Hooper’s, and the [E-independent] bar is not met: two guideline/review layers over one trial base is exactly the non-independence this page already flags for the WHO/ESC threshold agreement. [INFERRED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020; WHO - Saturated and Trans Fatty Acid Intake 2023) — each cell is quoted from its source; the non-independence reading is this page's]

The events-not-mortality finding, now stated by the primary source. This page derived exactly one outcome clears the null, and it is not mortality as an [INFERRED] reading of WHO’s Annex 6 (which WHO does not summarize this way). Hooper summarizes it exactly this way, as the review’s headline:

«We found little or no effect of reducing saturated fat on all-cause mortality (RR 0.96; 95% CI 0.90 to 1.03; 11 trials, 55,858 participants) or cardiovascular mortality (RR 0.95; 95% CI 0.80 to 1.12, 10 trials, 53,421 participants), both with GRADE moderate-quality evidence.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

So the inference this page made is upgraded to a directly-extracted claim — the F-move: the composite (WHO profile + Hooper’s own summary) removes the inference burden the earlier reading carried alone. The Moderate certainty on the mortality nulls is load-bearing — this is a well-graded null, not thin evidence, so reducing SFA does not measurably reduce dying is a reasonably-certain finding, not an absence of data. (The abstract’s mortality counts differ trivially from the SoF table — CV mortality RR 0.95 (0.80-1.12) / 10 trials in the abstract vs 0.94 (0.78-1.13) / 11 in the SoF; both near-Moderate, both spanning the null.) Authors’ conclusion:

«The findings of this updated review suggest that reducing saturated fat intake for at least two years causes a potentially important reduction in combined cardiovascular events.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

NNT / time-horizon framing (new — WHO gives 15-per-1000 but no NNT).

«This 17% reduction in risk of CVD events translated into a number needed to treat for an additional beneficial outcome (NNTB) of 56 in primary prevention trials, so that 56 people need to reduce their saturated fat intake over around four years for one person to avoid experiencing a CVD event. In secondary prevention trials, the NNTB was 53.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 02]

NNTB 56 (primary prevention) / 53 (secondary) over ~4 years restates the 15-fewer-per-1000 headline as a person-count against a time horizon — the form a decision actually uses. That the two settings are so close is mildly surprising, and it is not a consequence of the constant relative effect — the opposite: a constant RR makes absolute benefit scale with baseline risk (route (a), below), so the higher-baseline-risk secondary-prevention population should give a lower NNTB. The near-equality (56 ~ 53) instead reflects comparable baseline event rates and follow-up across the two trial sets, not the constancy of the relative effect.

Dose-response, with a mechanism (refines this page’s WHO greater reductions produced greater risk reduction). Hooper’s meta-regression locates the source of the between-trial heterogeneity (I2 = 67%):

«Meta-regression suggested that greater reductions in saturated fat (reflected in greater reductions in serum cholesterol) resulted in greater reductions in risk of CVD events, explaining most heterogeneity between trials.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

Two refinements over the bare WHO statement: the gradient runs through serum-cholesterol lowering (the dose-response is cholesterol-mediated, consistent with LDL ApoB and Cumulative Exposure), and Hooper reads the gradient as strengthening the causal claim — «This suggestion of a dose response strengthens our belief that there is a true effect of reducing saturated fat on CVD events.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 03]. It is a monotone dose-response on the events outcome (no knee located; more reduction, more benefit, over the studied range) — a data point for the dose-response-shape question -> The U-Shaped Association Artifact.

Effect-modification NULLS — the relative effect does not vary by stratum (route-b negatives).

«The reduction in combined cardiovascular events resulting from reducing saturated fat did not alter by study duration, sex or baseline level of cardiovascular risk, but greater reduction in saturated fat caused greater reductions in cardiovascular events.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

«People who are currently healthy appear to benefit as much as those at increased risk of heart disease or stroke (people with high blood pressure, high serum cholesterol or diabetes, for example), and people who have already had heart disease or stroke. There was no difference in effect between men and women.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

Decision-relevant because it fixes which stratification route applies. The relative effect (RR ~0.83) is constant across baseline CVD risk, sex and duration — so SFA reduction is a route-(a) case, not route-(b): personalize by baseline risk (absolute benefit scales with it -> Baseline Risk and the Relative-Absolute Split), not by a claimed effect-modifier. That is the same logic this page’s PUFA-vs-carbohydrate absolute-gap discussion already ran (23.8% vs 7.6% control-rate populations), now confirmed by a direct subgroup test rather than inferred from event rates. [INFERRED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) — the route-(a)-not-(b) reading is this page's; the subgroup nulls are Hooper's]

Replacement nutrient — PUFA and carbohydrate not distinguishable on hard events.

«Subgrouping did not suggest significant differences between replacement of saturated fat calories with polyunsaturated fat or carbohydrate, and data on replacement with monounsaturated fat and protein was very limited.» [EXTRACTED (Hooper - Saturated Fat Reduction Cardiovascular Cochrane 2020) chunk 01]

This is weaker than WHO’s structure (strong PUFA vs conditional carbohydrate): on hard CVD events, Hooper’s RCT subgrouping cannot separate PUFA from carbohydrate. Consistent with this page’s finding that PUFA’s edge is over-determined by the LDL magnitude while the replacement-specific event evidence is thin and imprecise — Hooper’s clean signal is of reducing SFA, pooled across replacements; the replacement contrast is underpowered.

The heterodox reassessment — Astrup et al. 2020 [2026-07-29]

Astrup - Saturated Fats Reassessment 2020 (a JACC narrative State-of-the-Art Review, 12 authors) argues the population SFA limit is not supported and should be replaced with food-based guidance. It contests threads on this page rather than adding new trials — the full joined issue is filed as Does Reducing Saturated Fat Reduce Cardiovascular Events (the vault’s 2nd tension). What it changes here:

• It AGREES with the mortality finding above. “Most recent meta-analyses of randomized trials and observational studies found no beneficial effects of reducing SFA intake on cardiovascular disease (CVD) and total mortality.” For mortality that is Hooper’s RR 0.96 — the reassessment and the Cochrane MA are the same result. So the apparent contradiction is narrower than the framing. [EXTRACTED (Astrup - Saturated Fats Reassessment 2020) chunk 01, Abstract]
• A comparator-contamination challenge to the classic diet-heart RCT base. The classic trials had partially hydrogenated fish oils (trans fats) in their control-arm margarines, so “the European diets are tests of polyunsaturated fats against trans-plus-saturated fats, which means that any effects described cannot be assigned to saturated fats alone”; “Dropping these 3 studies from a meta-analysis leaves the U.S. trial, which did not find a significant difference between groups for its primary CVD outcome.” Scope it: this targets the AHA Presidential Advisory’s 4-core-trial selection, NOT Hooper’s 13-trial pool — whether the contamination flips the pooled RR 0.83 is an untested inference (View B is a narrative review, and post-hoc exclusion carries the selection-bias risk it names). Unadjudicated here. [EXTRACTED (Astrup - Saturated Fats Reassessment 2020) chunk 01, From Single Nutrients to Whole Foods]
• The attribution is genuinely open: SFA harm or PUFA benefit? Even granting a lower CVD risk with PUFA-for-SFA substitution, it “could be attributed to a possible beneficial effect of polyunsaturated fatty acids and not necessarily to an adverse effect of SFAs.” Hooper’s own subgroup null (PUFA vs carbohydrate indistinguishable on events, quoted above) means the RCTs cannot separate the two. So the substitution sets the sign — the page’s existing rule — and avoid SFA is not what the events evidence licenses; replace SFA with PUFA/whole foods is. [EXTRACTED (Astrup - Saturated Fats Reassessment 2020) chunk 01, Evidence on the Health Effects of SF]
• SFA harm is conditioned on carbohydrate context (mechanism, directional). “It is important to distinguish between dietary saturated fat and circulating SFAs” — circulating even-chain SFAs predict disease, but “the amount of circulating SFAs in blood is not related to saturated fat intake from the diet but instead tends to track more closely with dietary carbohydrate intake” (a 2-3x SFA rise on a low-carb background leaves serum SFAs flat or lower, via reduced de novo lipogenesis + increased fat oxidation). A substrate-competition frame: the harm of a high-SFA diet is modulated by carbohydrate/insulin status. [INFERRED (Astrup - Saturated Fats Reassessment 2020) — the conditional-harm reading; the intake-vs-circulating dissociation is Astrup's]
• A claimed SFA-sensitive subgroup (route-b, unconfirmed). APOE4 / APOA2 gene-diet interactions lead Astrup to “It is this segment of the population (the SFA-sensitive) in which the reduction in SFA intake may be beneficial and could therefore be recommended” — but he concedes that “in the absence of randomized dietary intervention studies” these effects “cannot be attributed specifically to SFAs.” An effect-modification claim on observational gene-diet data — a route-(b) hypothesis, not a warrant for stratifying yet, and cutting against Hooper’s direct subgroup null (relative effect constant across baseline risk/sex/duration, the route-(a) finding above). [EXTRACTED (Astrup - Saturated Fats Reassessment 2020) chunk 01, Tailoring Dietary Saturated Fat Intake]

Astrup’s LDL-surrogate argument (diet-induced LDL-C may not track the atherogenic apoB-particle burden) is woven onto LDL ApoB and Cumulative Exposure; his food-matrix program (dairy, meat, chocolate) onto Is the Food Category Doing Any Work.

PURE 2017 — the observational arm, grounded (and its income confound) [2026-07-29]

Dehghan - PURE Fats Carbohydrate Mortality 2017 is the large prospective cohort (135 335 adults, 18 countries, median 7.4 y) that the Astrup reassessment leans on for its observational pillar — so this grounds the observational arm already referenced in Does Reducing Saturated Fat Reduce Cardiovascular Events with the actual data. It is F (grounding), not [E-independent]: it is the cohort base Astrup already cited, not a second independent route.

PURE’s SFA associations (quintile 5 [median 13.2%E] vs quintile 1 [2.8%E]):

• Total mortality HR 0.86 (0.76-0.99), p-trend 0.0088 — inverse (higher SFA, lower mortality).
• Stroke HR 0.79 (0.64-0.98), p-trend 0.0498 — inverse.
• Major CVD 0.95 (0.83-1.10), MI 1.17 (0.94-1.45), CVD mortality 0.83 (0.65-1.07) — all null.

[EXTRACTED (Dehghan - PURE Fats Carbohydrate Mortality 2017) chunk 01, Table 3]

Attempt the contradiction, then scope it. Read naively, PURE reverses this page: SFA lowers mortality, guidelines are wrong. The parameter table forbids that reading — PURE and the RCT evidence this page rests on are not the same quantity:

Parameter	PURE (Dehghan)	Hooper RCT / WHO Annex 6	Same quantity?
Design	observational cohort, FFQ at baseline	15 RCTs, assigned-diet, >=24 mo	NO — observational vs randomised
Exposure contrast	high vs low SFA intake (13% vs 3%E) across an income/diet gradient	reduce SFA vs usual, within-trial	NO — level-contrast vs change
Hard-outcome finding	SFA null on major CVD/MI/CVD death; inverse on total mortality + stroke	reducing SFA → CV events RR 0.83 (15 fewer/1000); mortality null	partial — both null on MORTALITY
Confounding structure	residual confounding by income (highest-carb = poorest, refined-carb subsistence diets); could not measure trans fat	randomisation balances confounders	NO — the whole point
Replacement modelled	carb→PUFA lowers mortality (HR 0.89); carb→SFA null on mortality, but lowers stroke (0.80)	SFA→PUFA lowers CV events; SFA→carb does not	near — both rank PUFA replacement first

The load-bearing weakness, stated plainly (the authors’ own). PURE’s highest-carbohydrate quintiles are dominated by low-income populations eating refined-carbohydrate subsistence diets; higher fat = higher income = better outcomes. The authors concede it twice: «high consumption of carbohydrate and low consumption of animal products might simply reflect lower incomes; residual confounding as a potential reason for our results cannot be completely excluded», and «differences in the ability to afford fats and animal proteins, which are more expensive than carbohydrates». [EXTRACTED (Dehghan - PURE Fats Carbohydrate Mortality 2017) chunk 01, Discussion] So the SFA-inverse and carb-harm signals are the mirror image of an income gradient, not a demonstration that SFA protects — a worked instance of the confounding machinery -> The U-Shaped Association Artifact.

What genuinely survives, and it is agreement not reversal. On mortality, PURE finds SFA null-to- inverse and the Hooper RCTs find reducing SFA null — both say reducing SFA does not measurably reduce dying, which this page already holds. On replacement, PURE independently ranks PUFA-for-carb first (HR 0.89), echoing the page’s PUFA-strong structure. Where PURE cannot speak is the one place the RCTs do: the SFA→CV-events RR 0.83. PURE’s own event outcomes (major CVD, MI, CVD death) are all null — but as an unrandomised level-contrast confounded by income, that null does not overturn the randomised events estimate.

One directional refinement PURE adds (mechanistic, via the companion Mente 2017 lipid paper). Higher SFA raised LDL but also HDL, and lowered triglycerides, TC/HDL and ApoB/ApoA1; higher carbohydrate lowered LDL but raised ApoB/ApoA1 (the stronger predictor) — so «predicting the net clinical effect based on considering only the effects of nutrient intake on LDL cholesterol is not reliable». [EXTRACTED (Dehghan - PURE Fats Carbohydrate Mortality 2017) chunk 01, Discussion] This grounds Astrup’s LDL-surrogate caveat with data -> LDL ApoB and Cumulative Exposure; it does not contradict LDL’s causal status (apoB is the agent), it says diet-induced LDL-C is a poor summary of the whole lipid change. [INFERRED (Dehghan - PURE Fats Carbohydrate Mortality 2017) — each cell is quoted; the not-the-same- quantity reading and the income-confound weighting are this page's]

Self-critique (PURE weave) [run 2026-07-29, before commit]. Laundered-E: PURE is explicitly F (grounding), NOT [E-independent] — it is the cohort base Astrup already cited, stated three times. Overclaim: the contrarian headline (fats safe, carbs harmful) is engaged with full data (symmetric standards — PURE is a large, well-conducted cohort, not dismissed) and then weighted down by the authors’ own twice-conceded residual confounding, not hand-waved; no claim that PURE overturns the RCT consensus survives. Parameter table: built before the prose, «same quantity?» = NO on design, exposure contrast and confounding structure — the same-quantity failure the rule exists to catch (an observational level-contrast read as if it were the randomised change). No new tension filed — the joined issue already exists and is not re-adjudicated here. Counter-passage: the RCT side is represented at its strongest (RR 0.83 events, the estimate PURE structurally cannot reach), so the agreement claim rests on the mortality nulls both sides share, not on suppressing the events signal.